Home ›
Leukemia Trials ›
NCT07355335
Ziftomenib + Mezigdomide in Adolesc. and Adults w/ R/R AML
The purpose of this study is to evaluate the safety and tolerability of mezigdomide in combination with ziftomenib in adolescent and adult participants with either KMT2A-rearranged (KMT2A-r) or NPM1-mutant relapsed or refractory acute myeloid leukemia (AML).
Trial Details
NCT ID NCT07355335
Phase PHASE1
Sponsor Massachusetts General Hospital
Status RECRUITING
Cancer Type Leukemia
Interventions
Locations (sample) Boston, Massachusetts, United States|42.35843,-71.05977 Boston, Massachusetts, United States|42.35843,-71.05977
Key Eligibility Criteria
Age ≥16 years during dose escalation portion of study, patients must weigh ≥40 kg. Age \>12 years during dose expansion portion of study, patients must weight ≥40 kg. Diagnosis of AML per the WHO Classification of Hematolymphoid Tumors (5th Edition) with documented KMT2A rearrangement or NPM1 cytoplasmic-type (NP… Patients with NPM1 mutated AML must either be FLT3 ITD wild type or have an ITD allelic ratio of \<0.05 (i.e. not eligible for a targeted FLT3 tyro…
For full eligibility, visit ClinicalTrials.gov .
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Leukemia Trials on Trialify →